Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1231 participants.
Also called NCT01930188
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,231 participants
- Sponsor
- Registry
-
NCT01930188 -
2012-004827-19 -
CTRI/2014/05/004626
-
- Other papers using this trial's data
- Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
- Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Argentina, Bulgaria, Czechia, Hong Kong SAR China, Hungary, India, Japan, Mexico, Norway, Portugal, Romania, Russia, South Africa, Spain, Sweden, Thailand, Türkiye, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01930188. Randomized; double masking; primary purpose treatment. Start 2013-12-02 (actual); primary completion 2015-10-12 (actual). Results posted on 2019-01-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes
- Acronym
- SUSTAIN™ 2
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- sitagliptin
- Intervention (Drug)
- placebo
- Intervention (Drug)
- placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01930188- Content hash
9871b5713ebdc9e0839826bfbb6e96acffa4c93e88cd0878396cdacc9501f1ba